Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 9/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 4/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276991 | 0.84 | KMT2A (0.49) | ACACBTLR9TLR8TLR7 | |
| SCHEMBL17108649 | 0.84 | KMT2A (0.49) | ACACBTLR9TLR8TLR7 | |
| SCHEMBL11402871 | 0.82 | ACACB (0.50) | ACACBPANK3OGA | |
| SCHEMBL13466381 | 0.81 | ACACB (0.52) | ACACBPANK3OGA | |
| SCHEMBL13187881 | 0.81 | ACACB (0.49) | ACACBPANK3OGA | |
| SCHEMBL10121068 | 0.81 | ACACB (0.49) | ACACBPANK3OGA | |
| SCHEMBL29929322 | 0.81 | ACACB (0.52) | ACACBPANK3OGA | |
| SCHEMBL18782870 | 0.78 | ACACB (0.47) | ACACBPANK3OGA | |
| SCHEMBL13155029 | 0.78 | ACACB (0.56) | ACACBPANK3 | |
| SCHEMBL12257614 | 0.78 | ACACB (0.47) | ACACBPANK3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | ACACB 3228/4885CCR6 3887/4885SOS1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.